Persistence of immunity in healthy adults aged ≥50 years primed with a hepatitis B vaccine 3 years previously

References

• Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34(6):1329–39; PMID:16249217; http://dx.doi.org/10.1093/ije/dyi206
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B vaccines WHO position paper. WER 2004; 79:255–63; PMID:15344666
   PubMedGoogle Scholar
• World Health Organization. Hepatitis B vaccines: WHO position paper – Recommendations. Vaccine 2010; 28(3):589–90; PMID:19896455; http://dx.doi.org/10.1016/j.vaccine.2009.10.110
   PubMedGoogle Scholar
• World Health Organization. Hepatitis B. Fact sheet no. 204. July 2013. Geneva: Switzerland.
   Google Scholar
• Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202(2):192–201; PMID:20533878; http://dx.doi.org/10.1086/653622
   PubMed Web of Science ®Google Scholar
• Pan CQ, Zhang JX. Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci 2005; 2(1):36–40; PMID:15968338; http://dx.doi.org/10.7150/ijms.2.36
   PubMedGoogle Scholar
• Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B Vaccines. Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Philadelphia: Saunders Elsevier; 2012; Chapter 15: 205–34.
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Factsheet for general public: Hepatitis B. Available at: http://www.ecdc.europa.eu/en/healthtopics/hepatitis_B/factsheet-general-public/Pages/factsheet-general-public.aspx (accessed 17 June 2014).
   Google Scholar
• Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009; 21(3):201–9; PMID:19571643; http://dx.doi.org/10.1007/BF03324904
   PubMed Web of Science ®Google Scholar
• deRave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994; 12(6):532–4; PMID:8036828; http://dx.doi.org/10.1016/0264-410X(94)90313-1
   PubMed Web of Science ®Google Scholar
• Looney RJ, Hasan MS, Coffin D, Campbell D, Falsey AR, Kolassa J, Agosti JM, Abraham GN, Evans TG. Hepatitis B immunization of healthy elderly adults; relationship between naïve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001; 21:30–6; PMID:11321236; http://dx.doi.org/10.1023/A:1006736931381
   PubMed Web of Science ®Google Scholar
• Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003; 21(25–26):3623–8; PMID:12922091; http://dx.doi.org/10.1016/S0264-410X(03)00399-2
   PubMed Web of Science ®Google Scholar
• Van Damme P, Minervini G, Liss C, McCarson B, Vesikari T, Boslego JW, Bhuyan PK. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin 2009; 5(2):92–7; PMID:18690015; http://dx.doi.org/10.4161/hv.5.2.6587
   PubMed Web of Science ®Google Scholar
• Gilbert CL, Klopfer SO, Martin JC, Schödel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum Vaccin 2011; 7(12):1336–42; PMID:22185811; http://dx.doi.org/10.4161/hv.7.12.18333
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Flores SA, Martin JC, Klopfer SO, Schödel FP, Bhuyan PK. A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series. Pediatr Infect Dis J 2010; 29(10):972–4; PMID:20724955; http://dx.doi.org/10.1097/INF.0b013e3181f1b3b6
   PubMed Web of Science ®Google Scholar
• Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two- and three- dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunogenic memory. Pediatrics 2001; 107(4):626–31; PMID:11335734; http://dx.doi.org/10.1542/peds.107.4.626
   PubMed Web of Science ®Google Scholar
• Giambi C, Bella A, Barale A, Montù D, Marchisio M, Oddone M, Zito S, Rapicetta M, Chionne P, Madonna E, Ciofi degli Atti ML. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008; 8:100; PMID:18662386; http://dx.doi.org/10.1186/1471-2334-8-100
   PubMed Web of Science ®Google Scholar
• Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Masse R, Dionne M. Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine. Hum Vaccin Immunother 2013; 9(8):1685–90; PMID:23744506; http://dx.doi.org/10.4161/hv.25015
   PubMed Web of Science ®Google Scholar
• Reinert P, Cinquetti S, Soubeyrand B, Biasio LR, Meghlaoui G, Thomas S, Watson M. Challenge with hepatitis B vaccine in children previously vaccinated with an hepatitis B containing combination vaccine. Adv Ther 2010; 27:28–38. [Erratum in Adv Ther 2010;27:192.]; PMID:20182924; http://dx.doi.org/10.1007/s12325-010-0005-x
   PubMed Web of Science ®Google Scholar
• Zanetti A, Parlato A, Roman∫ L, Desole MG, Ferrera G, Giurdanella F, Zuliani M, Richard P, Thomas S, Fiquet A. Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy. Vaccine 2012; 30(39):5770–5; PMID:22789511; http://dx.doi.org/10.1016/j.vaccine.2012.06.078
   PubMed Web of Science ®Google Scholar
• Zinke M, Kappes R, Kindler K. Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann KH, Gunasekaran R, et al. Immune memory to hepatitis B virus in 4–9-year-old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009; 5:592–8; PMID:19535920; http://dx.doi.org/10.4161/hv.9051
   PubMed Web of Science ®Google Scholar
• Carollo M, Palazzo R, Bianco M, Pandolfi E, Chionne P, Fedele G, Tozzi AE, Carsetti R, Romano L, Ausiello CM. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine 2013; 31:506–13; PMID:23174200; http://dx.doi.org/10.1016/j.vaccine.2012.11.029
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Roman∫ L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010; 10:755–761; PMID:20884297; http://dx.doi.org/10.1016/S1473-3099(10)70195-X
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet J-M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28:730–6; PMID:19892043; http://dx.doi.org/10.1016/j.vaccine.2009.10.074
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Crasta PD, Hardt K. Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg mothers. Hum Vaccin Immunother 2012; 8(7):896–904; PMID:22777097; http://dx.doi.org/10.4161/hv.19989
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Crasta P, Messier M, Jacquet J-M, Van Herck K. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined Hepatitis A and B vaccine. J Med Virol 2012; 84:11–17; PMID:22052690; http://dx.doi.org/10.1002/jmv.22264
   PubMed Web of Science ®Google Scholar
• Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46(7):1078–84; PMID:18444828; http://dx.doi.org/10.1086/529197
   PubMed Web of Science ®Google Scholar
• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9(3):185–94; PMID:19240757; http://dx.doi.org/10.1038/nri2508
   PubMed Web of Science ®Google Scholar
• Haynes L, Swain SL. Why aging T cells fail: implications for vaccination. Immunity 2006; 24(6):663–6; PMID:16782020; http://dx.doi.org/10.1016/j.immuni.2006.06.003
   PubMed Web of Science ®Google Scholar
• HBVaxPro: Summary of product characteristics Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000373/human_med_000813.jsp&mid=WC0b01ac058001d124 (accessed 24 October 2014).
   Google Scholar
• Lee AW, Vesikari T, Gilbert CL, Klopfer SO, Schödel FP, Bhuyan PK. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants. Vaccine 2011; 29(45):7942–8; PMID:21875633; http://dx.doi.org/10.1016/j.vaccine.2011.08.071
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, D'Ostilio A. The immune system in the elderly: I Specific humoral immunity. Immunol Res 1999; 20(2):101–8; PMID:10580635; http://dx.doi.org/10.1007/BF02786466
   PubMed Web of Science ®Google Scholar
• Paganelli R, Scala E, Quinti I, Ansotegui IJ. Humoral immunity in aging. Aging Clin Exp Res 1994; 6(3):143–50; PMID:7993921; http://dx.doi.org/10.1007/BF03324229
   PubMed Web of Science ®Google Scholar